EGFR and non-small cell lung carcinoma: This is interpreted to be the result of the existence of complex resistance mechanisms such as T790M secondary mutation and MET amplification in EGFR-mutated NSCLC, and the inability of HSP90 inhibitors to secure pharmacodynamic characteristics sufficient to stably degrade EGFR protein.